Urolithin A Side Effects: What Studies Report

Urolithin A is not a peptide but a small phenolic metabolite, and it appears frequently in mitochondrial and muscle-ageing research. A 2022 comprehensive review described urolithins as compounds produced by gut bacteria from dietary ellagitannins and ellagic acid, found in foods such as pomegranate, walnuts and certain berries, and noted that the ability to produce urolithin A varies between individuals according to gut microbiota composition (PMID 35118817). That variability matters for any discussion of tolerability, because the same dietary intake produces very different internal exposure between so-called urolithin metabotypes, as the same review reported (PMID 35118817).

This page summarises what published papers reported about safety, tolerability and adverse events. It does not describe how anyone should use the compound. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

Human Tolerability Data: What Studies Report

The most directly relevant safety information comes from a small number of controlled human trials. In the first-in-human clinical trial published in Nature Metabolism, researchers administered oral urolithin A as single doses and then as four weeks of daily dosing at levels up to 1,000 mg per day in elderly participants, and the study reported that the compound was safe and bioavailable and induced a molecular signature consistent with improved mitochondrial and cellular health (PMID 32694802). That trial was designed primarily as a safety and pharmacokinetic evaluation rather than an efficacy study, and the authors framed their conclusions in those terms (PMID 32694802).

A longer randomized clinical trial published in JAMA Network Open gave oral urolithin A to older adults for four months at daily doses up to 1,000 mg, and researchers reported that the intervention was safe and well tolerated over that period while examining muscle endurance and markers of mitochondrial health as outcomes (PMID 35050355). That four-month duration is, among the studies cited on this page, the longest reported human exposure window (PMID 35050355).

Pulling the human evidence together, a 2024 systematic review in Ageing Research Reviews examined published human studies of urolithin A in the context of targeting ageing, and the review reported that across the trials it included the compound was generally described as safe and well tolerated, while also noting the limited size and duration of the available human literature (PMID 39002645). A 2024 review in Sports Medicine discussing mitochondria as nutritional targets for muscle health during ageing likewise placed urolithin A among nutritional strategies under active investigation rather than among established interventions (PMID 39060742).

What "safe and well tolerated" does and does not mean

Trial reports use that phrase to describe what investigators observed in a defined group over a defined time. It is a descriptive statement about a sample, not a general guarantee. The first-in-human study enrolled elderly volunteers over weeks (PMID 32694802), and the four-month trial also studied older adults (PMID 35050355), so the populations represented in these safety statements are narrow. The 2024 systematic review explicitly flagged the small number and short duration of human urolithin A trials as a limitation when interpreting their conclusions (PMID 39002645).

Gastrointestinal Findings: What Studies Report

Because urolithin A originates in the gut, several papers examine gastrointestinal tissue directly, though mostly in animals and cells rather than as human adverse-event reporting. A 2024 study in the Journal of Nanobiotechnology used inflammation-targeted nanoparticles to deliver urolithin A in mouse models and reported that this delivery mitigated both chemically induced colitis and colitis associated with immune checkpoint inhibitor treatment (PMID 39533380). A 2023 preprint reported that urolithin A reduced Clostridioides difficile toxin expression and repaired toxin-induced epithelial damage in laboratory models (PMID 37546803); as a preprint, that work had not completed peer review at the time of posting, which is relevant to how much weight the finding carries.

Two cautions follow from the design of these papers. First, they tested the compound as an intervention against gut injury caused by something else, not as a source of gut injury, so they are not adverse-event data. Second, the 2024 colitis work used an engineered nanoparticle delivery system rather than plain oral administration (PMID 39533380), and findings tied to a specific delivery vehicle do not transfer automatically to other forms of exposure.

Gut Microbiota and Production Variability: What Studies Report

The 2022 review of urolithin metabolism reported that only some individuals harbour the bacterial capacity to convert ellagitannins efficiently into urolithin A, and it described the associated gut microbiota profiles and the bioactivities attributed to different urolithins (PMID 35118817). This is a safety-adjacent point rather than a side effect: interindividual differences in conversion mean that dietary studies and direct-administration studies are not measuring the same exposure (PMID 35118817).

A separate line of work looks at bacteria that make urolithin A. A 2023 paper in Foods characterised the genetic and probiotic properties of a urolithin A–producing strain, Enterococcus faecium FUA027, and researchers assessed strain-level characteristics relevant to its potential use (PMID 36900537). Strain-level safety assessment is standard in that field because the genus in question includes both benign and problematic members, and the study reported its evaluation at that level rather than making broader claims (PMID 36900537).

Chemical Class Questions: What Studies Report

Urolithins belong to the dibenzo-α-pyrone chemical family, which also includes fungal metabolites. A 2021 review in the International Journal of Molecular Sciences, titled "Natural Dibenzo-α-Pyrones: Friends or Foes?", surveyed this class and discussed both gut-microbiota-derived urolithins and structurally related fungal compounds whose toxicological profiles have raised concern (PMID 34884865). The review's framing is a reminder that shared chemical scaffolds do not imply shared toxicity, and that compound-specific data are needed for each member of the class (PMID 34884865).

Preclinical Studies Where Urolithin A Was the Protective Agent

A recurring pattern in the recent literature is urolithin A being tested against damage caused by drugs or disease models. A 2025 study in Free Radical Biology & Medicine reported that urolithin A–laden functional nanoparticles alleviated cisplatin-induced cardiotoxicity in mice by inhibiting inflammation-induced lymphangiogenesis (PMID 40516794). A 2023 paper in Aging Cell examined olanzapine-induced ageing and reported that impaired mitophagosome–lysosome fusion mediated the effect, with urolithin A used as a mitophagy-directed tool in that model (PMID 37828862). A 2025 Journal of Nanobiotechnology paper described a myogenic nano-adjuvant approach to orthopedic-related sarcopenia acting through mitochondrial homeostasis in macrophage–myosatellite metabolic crosstalk (PMID 40437492).

None of these were toxicology studies of urolithin A in people. They are mechanistic animal and cell experiments, frequently using nanoparticle carriers, and they cannot be read as evidence about human adverse events.

Study-by-Study Summary

Gaps in the Published Safety Record

Reading the cited papers together, several categories of information are simply absent rather than reassuring:

• Duration. The longest human exposure reported among these studies was four months (PMID 35050355), so multi-year data are not represented in this literature.
• Populations. The human trials cited here studied elderly and older adults (PMID 32694802, PMID 35050355); pregnancy, childhood and organ-impairment populations were not the subject of these reports.
• Drug interactions. The animal papers cited here used urolithin A alongside chemotherapeutic or antipsychotic agents in disease models (PMID 40516794, PMID 37828862), which is not the same as human interaction data.
• Delivery form. Several recent findings depended on engineered nanoparticle carriers (PMID 39533380, PMID 40437492), so results are tied to those specific systems.
• Publication status. At least one cited gut finding was a preprint (PMID 37546803), which had not completed peer review.

How to Read Adverse-Event Language in These Papers

Trial publications typically report adverse events by count, severity grading and whether investigators judged them related to the intervention. Phase 1–style studies such as the first-in-human urolithin A trial are powered to detect common, short-term events rather than rare ones, and that trial's stated purpose was safety and bioavailability assessment (PMID 32694802). Efficacy trials such as the four-month randomized study collect safety data as a secondary concern while testing functional outcomes (PMID 35050355). Systematic reviews then aggregate what individual papers reported, inheriting whatever gaps existed in the source studies, a limitation the 2024 review acknowledged (PMID 39002645).

For background on what urolithin A is, how mitophagy research developed, and how the outcome measures in these trials work, the PeptideU learning course on urolithin A covers that material; this page stays focused on the safety and adverse-event literature.

References

• The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans (Nature Metabolism, 2019)
• Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial (JAMA Network Open, 2022)
• Targeting aging with urolithin A in humans: A systematic review (Ageing Research Reviews, 2024)
• Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota (Molecular Nutrition & Food Research, 2022)
• Inflammation-targeted delivery of Urolithin A mitigates chemical- and immune checkpoint inhibitor-induced colitis (Journal of Nanobiotechnology, 2024)
• The microbial metabolite Urolithin A reduces C. difficile toxin expression and repairs toxin-induced epithelial damage (bioRxiv, 2023)
• Genetic and Probiotic Characteristics of Urolithin A Producing Enterococcus faecium FUA027 (Foods, 2023)
• Natural Dibenzo-α-Pyrones: Friends or Foes? (International Journal of Molecular Sciences, 2021)
• Urolithin A-laden functional nanoparticles alleviate cisplatin-induced cardiotoxicity in mice by inhibiting inflammation-induced lymphangiogenesis (Free Radical Biology & Medicine, 2025)
• Impaired mitophagosome-lysosome fusion mediates olanzapine-induced aging (Aging Cell, 2023)
• Myogenic nano-adjuvant for orthopedic-related sarcopenia via mitochondrial homeostasis modulation in macrophage-myosatellite metabolic crosstalk (Journal of Nanobiotechnology, 2025)
• Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing (Sports Medicine, 2024)